These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37935319)

  • 1. Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view.
    Shafeghat Z; Dorfaki M; Dehrouyeh S; Arab FL; Roozbehani M; Falak R; Faraji F; Jafari R
    Transpl Immunol; 2023 Dec; 81():101957. PubMed ID: 37935319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem cell-derived exosomes can alleviate GVHD and preserve the GVL effect in allogeneic stem cell transplantation animal models.
    Jiang Y; Zhao J; Wang M; Huang F; Li J; Liu R; Wan J; Hao S
    Front Immunol; 2023; 14():1284936. PubMed ID: 38124750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
    Zhao L; Chen S; Yang P; Cao H; Li L
    Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
    Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
    Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Ocular Graft-Versus-Host Disease.
    Harrell CR; Djonov V; Volarevic V
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.
    Polchert D; Sobinsky J; Douglas G; Kidd M; Moadsiri A; Reina E; Genrich K; Mehrotra S; Setty S; Smith B; Bartholomew A
    Eur J Immunol; 2008 Jun; 38(6):1745-55. PubMed ID: 18493986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
    Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
    Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
    Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
    Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantity and Quality Reconstitution of NKG2A
    Hu LJ; Zhao XY; Yu XX; Lv M; Han TT; Han W; Huang XJ
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):1-11. PubMed ID: 30142416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.
    Yin F; Battiwalla M; Ito S; Feng X; Chinian F; Melenhorst JJ; Koklanaris E; Sabatino M; Stroncek D; Samsel L; Klotz J; Hensel NF; Robey PG; Barrett AJ
    Stem Cells; 2014 May; 32(5):1278-88. PubMed ID: 24452962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel study on the immunomodulatory effect of umbilical cord derived mesenchymal stem cells pretreated with traditional Chinese medicine Asarinin.
    He H; Yang T; Li F; Zhang L; Ling X
    Int Immunopharmacol; 2021 Nov; 100():108054. PubMed ID: 34492537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
    Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
    Front Immunol; 2022; 13():959658. PubMed ID: 36189324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells.
    Liu W; Zhou N; Liu Y; Zhang W; Li X; Wang Y; Zheng R; Zhang Y
    Stem Cell Res Ther; 2021 Feb; 12(1):153. PubMed ID: 33637123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes Released From Human Bone Marrow-Derived Mesenchymal Stem Cell Attenuate Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Mice.
    Li KL; Li JY; Xie GL; Ma XY
    Front Cell Dev Biol; 2021; 9():617589. PubMed ID: 33889570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease.
    Kelly K; Rasko JEJ
    Front Immunol; 2021; 12():761616. PubMed ID: 34764962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.